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Abstract
Small cell lung cancer (SCLC) is the most aggressive type of lung cancer, with
almost 95% of patients succumbing to the disease. Although RBM5, a tumor
suppressor gene, is downregulated in the majority of lung cancers, its role in SCLC
is unknown. Using the GLC20 SCLC cell line, which has a homozygous deletion
encompassing the RBM5 gene locus, we established stable RBM5 expressing
sublines and investigated the effects of RBM5 re-expression. Transcriptome and
target identification studies determined that RBM5 directly regulates the cell cycle
and apoptosis in SCLC cells, as well as significantly downregulates other
important transformation-associated pathways such as angiogenesis and cell
adhesion. RNA sequencing of paired non-tumor and tumor SCLC patient
specimens showed decreased RBM5 expression in the tumors, and expression
alterations in the majority of the same pathways that were altered in the GLC20
cells and sublines. Functional studies confirmed RBM5 expression slows SCLC
cell line growth, and increases sensitivity to the chemotherapy drug cisplatin.
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Overall, our work demonstrates the importance of RBM5 expression to the non-
transformed state of lung cells and the consequences of its deletion to SCLC
development and progression.
Keywords: Cancer research, Cell biology
1. Introduction
According to the American Cancer Society, more people die from primary cancers
of the lung than from any other type of cancer. The most aggressive type of lung
cancer occurs in the “small cells”, found in the main bronchi (Travis et al., 2004).
Small cell lung cancer (SCLC) almost exclusively occurs in people with a history
of tobacco smoking (Jackman and Johnson, 2005; Travis et al., 2004).
Lung cancer initiation and progression are attributed at the molecular level to many
factors, but arguably the most interesting is the loss of heterozygosity in a few
regions throughout the short arm of chromosome three. Notably, allelic loss within
the 3p21.3 region is evidenced even in pre-neoplastic tissue from smokers
(Wistuba et al., 2000). An overlapping homozygous deletion within 3p21.3, noted
in lung and breast tumors, harbors a number of tumor suppressor genes (Lerman
and Minna, 2000). RNA Binding Motif 5 (RBM5), a putative lung cancer tumor
suppressor gene (Sutherland et al., 2010), resides near the end of the telomeric
deletion breakpoint that was noted in three SCLC cell lines (Lerman and Minna,
2000). In the majority of lung cancers (including SCLC and non-small cell lung
cancer (NSCLC)), expression of RBM5 is downregulated but present (Oh et al.,
2002). The cause of this downregulation is unknown, but does not appear to result
from gene mutation or promoter hypermethylation (Oh et al., 2008; Oh et al.,
2007), suggesting allelic loss may be responsible. The almost universal
downregulation of RBM5 in all types of lung cancer does suggest it plays an
important role in lung cancer initiation and/or progression. RBM5 was, in fact,
identified as one of nine downregulated genes within a 17 gene signature
associated with metastasis in various human solid tumors, including lung
(Ramaswamy et al., 2003).
Previous functional work relating to RBM5 in a variety of cancer cell lines
identified it as a modulator of the cell cycle and apoptosis, partially via its
influence on alternative splicing (Bechara et al., 2013; Oh et al., 2002). In regards
to lung cancer specifically, some functional work regarding RBM5 has been
performed using a lung adenocarcinoma cell line (A549), which showed that
increased RBM5 expression correlated with (a) G1 cell cycle arrest (Network,
2014; Shao et al., 2012), and (b) increased apoptosis (Oh et al., 2006; Shao et al.,
2012). No functional work, however, has been undertaken for RBM5 in SCLC.
This project set out to determine the importance of RBM5 in SCLC, in order to
better understand the consequences of its downregulation to the development and
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progression of this disease. Furthermore, since SCLC is the most aggressive type
of lung cancer, with 95% of patients eventually succumbing to the disease
(Govindan et al., 2006), it is clear that a better understanding of this disease, as
well as more effective treatment options, are required.
GLC20 is a SCLC cell line derived from small cells within a lung tumor biopsy (Smit
et al., 1992). The cells have two 3p21 homozygous deletions, one of which includes
RBM5, making the cells an attractive model in which to study the functional
consequences of RBM5 re-expression (Angeloni, 2007; Kok et al., 1994). We
established two RBM5 expressing populations, with different levels of RBM5, and
conducted transcriptome analyses to identify the pathways affected by altering the
levels of RBM5. Target identification experiments were carried out to determine
which of these pathways were directly affected by RBM5. To validate our findings,
we (a) compared our in vitro transcriptomic results to transcriptomic data from two
paired non-tumor/tumor patient specimens with a 50% downregulation of RBM5
expression, and (b) experimentally examined the effects of no versus low versus high
RBM5 expression on cell proliferation and apoptosis. Our results suggest that RBM5
is a key SCLC suppressor and guardian of the non-transformed phenotype.
2. Results & discussion
2.1. Establishment of a GLC20 model for SCLC studies relating
to RBM5
GLC20 cells are RBM5-null and were established from a tumor that was multidrug
resistant (doxorubicin, cyclophosphamide and vincristine), a common characteristic
of advanced SCLC. As depicted in Fig. 1A, the breakpoint for the GLC20 deletion is
upstream of RBM5, and the entire RBM5 gene is deleted (Lerman and Minna, 2000).
We verified the absence of RBM5 DNA, RNA and protein (Fig. 1B–E).
To better understand the impact of RBM5 downregulation on SCLC, stable
populations of RBM5 expressing cells were established. Two RBM5-expressing
sublines were established, one clonal (designated GLC20.C4 or “C4”) and one
from a pooled population of RBM5-expressing transfectants (designated GLC20.T2
or “T2”) (Fig. 1F). We also established an empty vector control subline (GLC20.
pcDNA3 or “pcDNA3”).
To ensure that a GLC20 model would be useful for functional studies relating to
RBM5, chiefly known as a modulator of apoptosis, we examined their cell death
profile when exposed to various apoptogenic agents. The highly resistant nature of
GLC20 cells to chemotherapy was demonstrated (Fig. 2), since cisplatin exposure,
without etoposide, required a concentration of 80 μg/ml (226 μM) to be somewhat
effective at promoting apoptosis by 24 h post exposure (Fig. 2A, lanes 1–3).
GLC20 cells are, however, capable of undergoing apoptosis, since PARP cleavage
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was observed 24 h following co-administration of 10 μg/ml (33 μM) cisplatin and
10 or 20 μg/ml (17 or 34 μM) etoposide (Fig. 2A, lanes 4–9), and almost complete
following 40 to 48 h incubation with these agents (Fig. 2B lanes 4–9). Thus,
although these cells are highly drug resistant, they are capable of experiencing
cisplatin-mediated apoptosis.
2.2. RNA-Seq shows that over 12% of the transcriptome is
differentially expressed by RBM5 in GLC20 cells, SLC25A53 is
the most altered gene, and pathways relating to cancer are the
most likely impacted
To investigate if and how RBM5 expression influences GLC20 cells, deep
sequencing of the transcriptome (RNA-Seq) of the parental GLC20 cells and three
[(Fig._1)TD$FIG]
Fig. 1. Characterization of wildtype GLC20 cells and RBM5 expressing sublines. (A) Cartoon of
location of deletion breakpoints in various lung cell lines. (B) Genomic DNA PCR results from different
cell lines. (C) RBM5 Southern Blot. (D) RT-PCR results from different cell lines. (E) Western Blot. (F)
RBM5 expression in GLC20 stable transfectants by RT-PCR and Western Blot. (G) Cartoon of 5′ end of
RBM5 gene, not drawn to scale, showing approximate locations of various probes. Box marked “W”:
Western antibody LUCA-15 UK; box marked “S”: Southern probe; RT-PCR primers LU15(2) and
LU15(3) (black thin open arrowheads); genomic PCR primers Gen1E2Fc and Gen2E3I2R (red thick
arrows). See Figure S1 for full gel of B, D and F, and full blot of E and F.
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sublines was carried out. See Materials & methods for an explanation of the
“control” used in sequencing analyses.
Firstly, we confirmed RBM5 expression levels within the transcriptomic data for
T2 and C4 (Fig. 3A). Differential expression testing (refer to Materials & methods)
identified that 12.5% of the transcriptome examined was significantly differentially
expressed between control and T2, and 18.4% between control and C4 (Fig. 3B).
Furthermore, over 50% of the genes that were differentially expressed in T2 were
also differentially expressed in C4, suggesting that any effect in C4 is not likely the
result of a clonal effect related to subclone establishment. Solute Carrier Family 25
Member 53 (SLC25A53) was the most significantly differentially expressed gene in
both T2 and C4 compared to control (based on log2 (fold-change); 1112.1 FPKM
(Fragments Per Kilobase of transcript per Million mapped reads) to 0.068 FPKM in
control vs. C4, and 1127.3 FPKM to 0.073 FPKM in control vs. T2). This gene is
part of a large family of transporters that control various cellular functions,
although a particular role for SLC25A53 has yet to be identified (Palmieri, 2013).
Other highly downregulated genes common to both T2 and C4 include CD9, Discs
Large Homolog Associated Protein 1 (DLGAP1), and Feline Sarcoma (FES).
Interestingly, CD9 and FES have previously been associated with cell adhesion and
tumor metastasis, with the effect of their expression seeming to be cell type-
specific (Delfino et al., 2006; Huan et al., 2015; Kanda et al., 2009; Rappa et al.,
2015). Of the two, only CD9 has been investigated in regards to SCLC specifically,
and low expression levels were linked to increased motility and invasiveness
(Funakoshi et al., 2003). The fact that RBM5 expression decreased CD9 expression
was thus unexpected, as we hypothesized that RBM5 would promote a non-
[(Fig._2)TD$FIG]
Fig. 2. Apoptosis induction by various apoptogenic stimuli. GLC20 cells were treated with cisplatin
with or without etoposide, for the various times indicated. Details in Materials & methods. See Figure
S2 for full blots.
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transformed state in SCLC cells. However, CD9 gene expression levels in our
control were much lower than those in our clinical SCLC tumor samples (described
below) (average of 6.6 FPKM in our cell line control and 109.1 FPKM in tumor
samples), suggesting that although RBM5’s influence on CD9 may be statistically
significant, it may not be physiologically relevant in our system.
On the other hand, two genes other than RBM5 were highly upregulated in both T2
and C4 compared to control; MKRN3 and ZNF85. Of note, the former has been
previously associated with development, particularly the onset of puberty, which is
in line with the pathway results presented below (Abreu et al., 2013).
Using two different pathway analysis programs, we went on to determine the
functional implications of genes differentially expressed upon expression of RBM5.
First, the Functional Interpretation of Differential Expression Analysis (FIDEA)
(D'Andrea et al., 2013) program with the Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathway database (Kanehisa and Goto, 2000; Kanehisa et al.,
[(Fig._3)TD$FIG]
Fig. 3. Transcriptome analysis of GLC20 sublines. (A) RBM5 expression in control, T2 and C4 samples
as determined by RNA-Seq. **p < 0.01. (B) Venn diagram demonstrating significantly differentially
expressed genes between T2 and C4 compared to control, respectively, as determined by RNA-Seq.
Number of genes in each group indicated in parenthesis. (C and D) FIDEA pathway analysis results for
altered KEGG pathways in control vs T2 (C) and C4 (D) samples, respectively, from RNA-Seq
transcriptome data. (E) GSAASeqSP blue-pink o’gram representing the expression levels of core
enriched genes within the MSigDB Angiogensis Hallmark gene set in control and C4 (RNA-Seq data).
Blue indicates low expression, whereas red indicates high expression levels. Genes listed in order of
Rank Metric Score. (F) KRAS and SOX2 expression in control and C4 samples as determined by RNA-
Seq.
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2014) was used, thus differentially expressed genes are placed in known signaling
pathways to determine if these pathways are significantly up- or downregulated.
Analysis results are presented in Fig. 3C and D. Pathways in cancer was
significantly downregulated in both T2 and C4 compared to control. Other
transformation-related pathways were also downregulated upon RBM5 expression
in T2 such as the cell cycle, small cell lung cancer and pancreatic cancer. The fact
that these pathways were not also significantly changed in C4 may be due to the
larger number of differentially expressed genes in this sample, which may mask the
effect of RBM5 on these particular cancer-related pathways. In addition, both axon
guidance and alcoholism were significantly altered in both T2 and C4. This is very
interesting since axon guidance, as well as alcoholism, have been shown to play a
substantial role in cancer development and progression (Chedotal et al., 2005;
Forsyth et al., 2010).
To complement our KEGG pathway results, we used an additional pathway
analysis program − the Gene Set Association Analysis for RNA-Seq with Sample
Permutation (GSAASeqSP) program (Xiong et al., 2014) - as it takes into account
inherent bias present in RNA-Seq data. In combination with the Broad Institute’s
Molecular Signatures Database (MSigDB) Hallmark gene set (Liberzon et al.,
2015), genes are grouped based on established biological processes, and enriched
gene sets determined. We identified 12 and 17 gene sets with false discovery rates
(FDR) at or below 10% in T2 and C4, respectively, compared to control. Over half
of these T2 altered gene sets were common to C4, once again suggesting that any
effect seen in C4 is not likely due to a clonal effect related to subclone
establishment. Gene sets with FDR at or below 10% in control vs. C4 are presented
in Table 1, along with their FDR in control vs. T2. Interestingly, many
differentially expressed gene sets are important to development, which validates
our experimental findings, as RBM5 was recently shown to be involved in
myogenesis, spermatogenesis and neuronal development (Fushimi et al., 2008;
Loiselle and Sutherland, 2014; O'Bryan et al., 2013). Furthermore, apoptosis and
TNFα signaling, both pathways RBM5 has been previously associated with in
Jurkat T lymphoblastoid cells (Rintala-Maki and Sutherland, 2004; Sutherland
et al., 2000) and MCF-7 cells (Rintala-Maki et al., 2004) were altered in T2 and
C4. Fig. 4 lists the core enriched genes in these gene sets and how their expression
changed upon RBM5 expression in C4, highlighting the importance of RBM5 to
these cellular functions.
Other gene sets identified in this GSAASeqSP analysis are important to the
transformed state, supporting our KEGG pathway results and providing additional
insight into the role of RBM5 in SCLC cells. These gene sets (Table 1) include
genes involved in (a) angiogenesis, where RBM5 expression (in T2 and C4)
correlated with significantly decreased expression of pro-angiogenic factors, such
as Vascular Endothelial Growth Factor A (VEGFA) (Fig. 3E), (b) epithelial-
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mesenchymal transition (EMT), and (c) the immune response. RBM5 may,
therefore, not only promote a non-transformed state, but be important for
identification and elimination of cells that adopt cancerous characteristics.
Taken together, these RNA-Seq pathway analysis results for the GLC20 sublines
indicate that in SCLC cells, RBM5 expression is very important to the maintenance
of the non-transformed state, particularly via regulation of cell death, angiogenesis,
cell-cell adhesion and immune response pathways.
2.3. RBM5 regulates expression of SCLC-associated genes
To investigate the influence of RBM5 expression particularly on SCLC-associated
pathways, we examined the expression of previously identified lung cancer-
associated genes in our GLC20 sublines. In a report released by the National
Table 1. Altered gene sets with FDR below 10% between control and C4 samples,
as determined by GSAASeqSP analysis with the MSigDB Hallmark gene set using
the samples’ RNA-Seq results. Ranked based on FDR value in control vs. C4
analysis. FDR value in control vs. T2 samples is also indicated for the given
pathways. Italics indicates FDR values above 10%.
Control vs. C4 Control vs. T2
Gene Set FDR FDR
Hedgehog signaling 0.000 0.033
Angiogenesis 0.000 0.067
Apoptosis 0.054 0.28
Androgen response 0.058 0.067
Myogenesis 0.064 0.183
Estrogen response late 0.064 0.033
TNFα signaling via NF-κB 0.070 0.075
Coagulation 0.071 0.115
IL2 STAT5 signaling 0.075 0.125
UV response down 0.076 0.226
Apical surface 0.078 1.000
Cholesterol homeostasis 0.080 0.113
IL6 JAK STAT3 signaling 0.083 0.147
Estrogen response early 0.087 0.057
Inflammatory response 0.094 0.432
KRAS signaling up 0.100 0.114
Epithelial to mesenchymal transition 0.100 0.073
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Cancer Institute (NCI) in June 2014, entitled Scientific Framework for Small Cell
Lung Cancer, a list of 37 ‘Genes of Interest in SCLC’ was compiled. Interestingly,
the expression of 43.2% of these ‘Genes of Interest in SCLC’ (16/37) significantly
changed expression in C4, compared to control (Table 2), with 11 of these
differentially expressed genes changing expression in a manner that would promote
suppression of tumor growth upon RBM5 expression; BCL2, CCNE1, COBL,
CREBBP, EPHA7, MED12L, MYCL1, RAB37, SLIT2, SMO and SOX2. Further-
more, 11 of the 21 non-differentially expressed genes had very low expression in
the control and C4 (FPKM below one), and thus may not play an important role in
[(Fig._4)TD$FIG]
Fig. 4. Expression changes of core enriched genes in RBM5-altered gene sets. GSAASeqSP blue-pink
o’gram representing the expression changes of core enriched genes from the MSigDB Hallmark
Apoptosis (A) and TNFα signaling via NFκB (B) gene sets in control vs. C4 samples (RNA-Seq data).
Blue indicates low expression, whereas red indicates high expression. Genes listed in order of Rank
Metric Score.
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Table 2. Expression of NCI ‘Genes of Interest in SCLC’ in control and C4
samples, as determined by RNA-Seq. Expression values are expressed as FPKM.
Italics identify genes with non-significant differential expression between control
and C4 and expression below one FPKM in both samples.
Gene name Control C4 p-value Significance
BCL2† 1.8307 0.2914 0.00005 Yes
CCNE1† 18.139 10.6106 0.00005 Yes
CDK14‡ 17.0371 19.8042 0.0083 Yes
CDKN2A 78.3537 89.0263 0.0378 No
COBL† 0.885007 0.011419 0.004 Yes
CREBBP‡ 5.47952 6.5709 0.0018 Yes
DMBX1 0.048243 0.102193 1 No
EP300 7.62326 7.82019 0.789641 No
EPHA7‡ 20.1031 26.6501 0.0001 Yes
FGFR1 0.171331 0.212293 1 No
GPR113 0.475767 0.661619 0.6777 No
GPR133 0.003737 0 1 No
GPR55 0.001965 0 1 No
GRID1 0.553261 0.587185 0.6624 No
LRRK2 0.068785 0.016732 1 No
MED12L† 3.18195 0.191165 0.00005 Yes
MLL (KMT2A) 11.1758 11.5143 0.5842 No
MYCL† 11.114 8.99515 0.0044 Yes
NOTCH1‡ 4.87757 6.22612 0.00005 Yes
NOTCH2‡ 3.44146 4.85108 0.00005 Yes
NOTCH3 0.06277 0.11642 1 No
PIK3CA 9.39427 8.64243 0.1883 No
PPEF2 0.037315 0.063875 1 No
PRKD3 26.8136 28.0848 0.4054 No
PTEN† 17.1134 14.0056 0.0007 Yes
PTPRD 0 5.72938 1 No
RAB37† 0.660452 0.186656 0.00005 Yes
RASGRF1 0.00182 0.006163 1 No
RASGRF2 0.377979 0.006163 1 No
RB1 6.22425 6.86606 0.1533 No
RUNX1T1‡ 5.11373 8.39718 0.00005 Yes
SLIT2‡ 5.19232 9.74325 0.00005 Yes
SMO† 5.93771 3.35434 0.00005 Yes
SOX2† 14.0653 10.8382 0.0003 Yes
(Continued)
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GLC20 cells. The observation that RBM5 expression influences the expression
levels of so many NCI-collated ‘Genes of Interest in SCLC’ highlights (1) the
importance of RBM5 to SCLC, (2) the impact that RBM5 gene deletion may have
on the development of lung cancer, and (3) the effect that re-establishment of
RBM5 expression may have on SCLC tumors.
In addition to these NCI-collated ‘Genes of Interest in SCLC’, we examined the
influence of RBM5 expression on Sex-determining region Y-box 2 (SOX2) and
Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS), as overexpression of the
former has been observed in many types of lung cancers and is linked with tumor
initiation (Tam and Ng, 2014), and activation of the latter occurs in approximately
30% of smoking-associated lung adenocarcinomas (Unni et al., 2015). In our C4
samples, SOX2 and KRAS were significantly downregulated (Fig. 3F), suggesting
once again the importance of RBM5 expression in lung tissue.
2.4. Alternative splicing accounts for a minority of the
differential gene expression
RBM5 influences processes such as apoptosis and cell cycle arrest in a variety of
cancer cell lines at least in part via the modulation of alternative splicing of key
factors, such as NUMB and CASPASE 2 (CASP2) (Bechara et al., 2013; Fushimi
et al., 2008). To see if RBM5 influences processes in SCLC via modulation of
alternative splicing, we mined our RNA-Seq data for significant alternative
splicing changes.
In the control vs. T2 group, 2,546 variants were significantly differentially
expressed (5.12% of the 49,772 variants examined), with 10 genes showing a
significant change from one alternative splice variant to another (Table 3). In the
control vs. C4 group, 4,180 variants were differentially expressed, with 47 genes
showing a significant change from one alternative splice variant to another
(Table 4). The greater number of alternative splicing events occurring in the C4
subline, compared to T2, suggests an additive effect of RBM5 on alternative
splicing, which was expected. There was no overlap, however, of splicing events
between T2 and C4, potentially due to the stringent search parameters used, and no
Table 2. (Continued)
Gene name Control C4 p-value Significance
STK38 20.2447 18.0817 0.0533 No
TP53 2.85615 3.40231 0.2023 No
TRRAP 13.9452 12.2657 0.0716 No
† Indicates genes significantly downregulated in C4.
‡ Indicates genes significantly upregulated in C4.
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significant enrichment of these splicing events in any KEGG pathway or MSigDB
Hallmark gene set. Furthermore, the number of significant alterations in splicing
between control and T2 and C4, respectively, was much lower than expected, given
the high number of differentially expressed genes (even considering the stringent
search parameters). This suggests that modulation of alternative splicing is not the
only means by which RBM5 influences important transformation-associated
pathways in SCLC. RBM5 may, for instance, regulate gene expression levels by
influencing transcription or stabilizing transcripts, as has been shown for other
RNA-binding proteins, including the RBM5-related protein RBM10 (Guallar and
Wang, 2014; Mueller et al., 2009). We therefore proceeded to carry out binding
studies in order to identify targets with which RBM5 interacts, either directly or
indirectly, and thereby gain a better understanding of how RBM5 influences the
identified pathways.
Table 3. Genes with at least one alternative splice variant significantly
upregulated, and at least one alternative splice variant significantly downregulated
between control and T2 (RNA-Seq results). Each row indicates expression levels
of a different variant for the given gene. Arranged alphabetically, by gene.
Control vs. T2
Gene name Log2 (fold-change) p-value q-value
BAG6 0.633915 0.0002 0.00279
-2.0923 0.0027 0.03018
EML1 1.18146 0.004 0.04069
-0.321613 0.0019 0.02236
FERMT2 -0.682011 0.0012 0.01589
0.326233 0.0039 0.04029
INF2 -0.707866 5e-05 0.00106
1.40674 5e-05 0.00106
IQCE -1.59194 0.0004 0.00645
0.571945 0.0045 0.04469
KCTD15 0.509451 0.0006 0.00906
-0.932889 5e-05 0.00106
KIF2A 1.13138 5e-05 0.00106
-1.01307 5e-05 0.00106
LIG3 1.44254 0.0003 0.00434
-0.360436 0.0007 0.01032
LIPA 0.547552 0.0005 0.0078
-0.676966 5e-05 0.00106
ZBTB14 -1.18342 0.0025 0.02843
2.62976 0.001 0.01382
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Table 4. Genes with at least one alternative splice variant significantly
upregulated, and at least one alternative splice variant significantly downregulated
between control and C4 (RNA-Seq results). Each row indicates expression levels
of a different variant for the given gene. Arranged alphabetically, by gene.
Control vs. C4
Gene log2 (fold-change) p-value q-value
ADAM22 0.983 8E-04 0.007
-0.691 0.006 0.0374
ADAT2 -0.412 0.002 0.0155
0.885 1E-04 0.0011
AR 0.444 5e-05 0.0006
-0.979 0.002 0.0119
ASAP1 -0.454 0.003 0.0219
0.722 5e-05 0.0006
ASPH 1.693 1E-04 0.0011
-0.679 0.005 0.0327
ATG16L1 0.718 5e-05 0.0006
-0.648 0.003 0.0204
BCKDHB 0.544 0.004 0.0242
-0.531 2E-04 0.0016
BZW2 -1.239 0.001 0.0091
0.281 0.002 0.0125
C14orf93 -1.649 8E-04 0.0066
1.096 0.002 0.0149
C8orf59 -0.413 0.004 0.0267
0.564 0.001 0.0098
CDK13 0.711 1E-04 0.0011
-0.303 0.003 0.0201
CEP41 1.715 0.006 0.0395
-0.482 5e-05 0.0006
CEP78 -1.025 5e-05 0.0006
1.100 5e-05 0.0006
CTNNB1 0.498 0.004 0.0281
-0.689 5e-05 0.0006
DMTF1 -0.427 0.002 0.0155
1.026 0.001 0.0091
DST -0.791 5e-05 0.0006
0.740 4E-04 0.0034
GGA1 1.047 8E-04 0.007
(Continued)
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Table 4. (Continued)
Control vs. C4
Gene log2 (fold-change) p-value q-value
-1.099 0.002 0.0161
1.028 0.001 0.0091
HMGXB4 0.567 5e-05 0.0006
-0.764 5e-05 0.0006
KIAA1958 1.630 1E-04 0.0011
-1.107 4E-04 0.0034
LIMA1 1.434 0.003 0.0213
-0.742 5e-05 0.0006
MAPKAP1 0.660 5e-05 0.0006
-0.474 0.001 0.0105
MUM1 0.479 0.004 0.0248
-0.875 5e-05 0.0006
MYO1B 0.763 5e-05 0.0006
0.906 0.001 0.0098
-1.790 0.004 0.0273
NAP1L1 -0.41 0.001 0.0109
0.404 0.002 0.0167
NUMB -1.472 0.008 0.0499
0.951 0.005 0.0314
-0.516 8E-04 0.0066
PAXBP1 -1.167 0.005 0.0319
1.058 5e-05 0.0006
PCBP2 -1.724 0.002 0.0177
0.652 0.006 0.0356
PDE1C -0.722 8E-04 0.007
0.911 5e-05 0.0006
PDHA1 -0.269 0.007 0.0435
2.175 0.003 0.0195
PHF8 0.834 2E-04 0.0021
-0.396 0.006 0.0374
PTK2 0.558 0.003 0.0231
-0.666 5e-05 0.0006
RAC1 0.297 0.006 0.0389
-1.588 5e-05 0.0006
RBBP5 -1.255 5e-05 0.0006
0.472 0.002 0.017
(Continued)
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2.5. RIP-Seq identified RBM5 RNA targets regulate RNA
metabolism and cell cycle pathways, ZNRF3 being the most
enriched gene
Although some studies have investigated RBM5’s binding motif (Bechara et al.,
2013; Ray et al., 2013), the number of identified RNA targets that are directly
bound by RBM5 is low. In cancer cell lines, only three directly bound RNA targets
have been identified to date; Caspase-2 (CASP2) (Fushimi et al., 2008), the
Table 4. (Continued)
Control vs. C4
Gene log2 (fold-change) p-value q-value
RBFOX2 0.971 5e-05 0.0006
-0.499 3E-04 0.0026
RPAP3 -1.041 0.005 0.0309
0.308 0.005 0.0303
RTN1 0.501 4E-04 0.0034
-2.439 3E-04 0.003
SLC29A1 -0.849 5e-05 0.0006
0.395 0.005 0.0325
SLC9A6 -1.393 5e-05 0.0006
0.492 0.006 0.0364
SSBP3 0.785 5e-05 0.0006
-0.597 3E-04 0.003
SYT1 1.903 5e-05 0.0006
-5.079 1E-04 0.0011
TPM1 1.473 5e-05 0.0006
-0.922 0.004 0.0258
UGGT1 0.626 5e-05 0.0006
-0.95 5e-05 0.0006
UPF3B 0.927 5e-05 0.0006
-1.231 5e-05 0.0006
ZBTB20 -1.234 0.004 0.0261
0.746 6E-04 0.0055
ZNF260 0.424 2E-04 0.0021
-0.933 0.001 0.0098
ZNF566 0.791 0.004 0.0273
-0.804 5E-04 0.0043
ZNF655 -1.174 0.005 0.034
0.690 0.007 0.0425
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antisense transcript of FAS (FAS-AS1) (Sehgal et al., 2014), and Activation-
induced cytidine deaminase (AID) (Jin et al., 2012). In mouse spermatid
differentiation, 11 RNA targets have been identified (O'Bryan et al., 2013). In
its capacity as a component of spliceosomal complexes (Hegele et al., 2012; Niu
et al., 2012), RBM5 is also likely capable, however, of binding many important
RNA targets indirectly (e.g., via another protein within the complex).
In order to identify direct and indirect RNA targets of the RBM5 protein in GLC20
cells, we used RNA Immunoprecipitation followed by next generation sequencing
(RIP-Seq). RIP-Seq experiments were performed using our non-commercially
available RBM5-specific LUCA-15UK antibody (Sutherland et al., 2000) because,
as demonstrated in Fig. 5, the commercially available antibodies that were tested
were not specific for RBM5. Two different negative controls were used in each of
two RIP-Seq replicates, to ensure the validity of identified RBM5 targets. Firstly, a
non-specific IgG IP in C4 cells (vs. LUCA-15UK IP in C4 cells), and secondly,
LUCA-15UK IP in GLC20.pcDNA3 cells (vs. LUCA-15UK IP in C4 cells).
Western blots showing successful IP of RBM5 for both replicates are presented in
Fig. 6A.
RNA from both RIP-Seq experiments was sequenced. The distribution of gene
expression values in our control vs. RBM5 RIP samples is presented in Fig. 6B, for
genes with FPKMs < 5000 (10 genes had FPKMs above 5000). This figure
highlights the high level of gene expression in our RBM5 RIP samples, compared
to the control, confirming the success of our technique. We identified 773 genes as
RBM5 targets (see Materials & methods for exclusion details), a not unexpectedly
large number since this technique identifies all RNA bound by a complex of which
RBM5 is a part.
The most significant RBM5 targets included Zinc & ring finger 3 (ZNRF3),
Suppressor of cancer cell invasion (SCAI), Growth factor receptor-bound protein 2
(GRB2), Zw10 kinetochore protein (ZW10), DEP domain containing (DEPDC1)
and Activating transcription factor 2 (ATF2). None of these genes were detected in
the control IP and all had FPKM values above 350 in the RBM5 RIP (ZNRF3 had
the highest count with 1.23 × 107 FPKM, followed by SCAI with 2866.53 FPKM
and GRB2 with 1482.74 FPKM). Interestingly, these six genes have all been shown
to play important roles in the control of the cell cycle and proliferation. It is
important to note that the previously identified direct RBM5 targets - CASP2, FAS
and AID - were not identified in our RIP-Seq experiments. Lack of detection of
these potentially direct targets could be a cell type-specific phenomenon, since
neither FAS nor AID were expressed above 0.1 FPKM in our samples.
To determine the importance of these targets to cellular functions, pathway
analysis was carried out on RIP-Seq identified RBM5 RNA targets. FIDEA
analysis, using the KEGG database, identified only three significantly changed
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pathways; ‘Spliceosome’ (hsa03040) (with a Benjamini value of 1.37 × 10−4),
‘RNA transport’ (hsa03013) (1.53 × 10−3) and ‘Ribosome’ (hsa03010) (9.07 ×
10−3). These results support our findings that RBM5 influences important
pathways in SCLC via regulation of alternative splicing and other pre- and/or post-
transcriptional processes. These results also help to confirm the success of our
technique, since RBM5 was previously shown to be a key component of
spliceosomal complexes (Hegele et al., 2012; Niu et al., 2012).
As with our RNA-Seq data, we used an additional pathway analysis program to
support our results. For this RIP-Seq data, our second program was Cytoscape with
[(Fig._5)TD$FIG]
Fig. 5. RBM5 antibody testing. The same whole cell lysate from either GLC20 cells (wt) or GLC20.C4
RBM5 containing cells (C4) was loaded in alternate lanes and probed with the antibodies indicated. The
LUCA-15-UK blot was probed with a 1:1000 antibody dilution, overnight at 4 °C, and exposed for 2
min. The upper Origene blot was probed with a 1:3000 antibody dilution, for 3 h at RT, and exposed for
60 min. The lower Origene blot was reprobed with a 1:500 antibody dilution, overnight at 4 °C, and
exposed for 60 min. The upper Abnova blot was probed with a 1:500 antibody dilution, for 3 h at RT,
and exposed for 60 min. The lower Abnova blot was reprobed with a 1:350 antibody dilution, overnight
at 4 °C, and exposed for 60 min. The Abcam blot was probed with a 1:2500 antibody dilution, overnight
at 4 °C, and exposed for 5 min. The Sp1 and Sp2 blots were probed with a 1:5000 antibody dilution, for
3 h at RT, and exposed for 1 min. All commercially available antibodies (therefore excluding Sp1 and
Sp2 – a gift from Juan Valcárcel − and LUCA-15-UK) interacted with product around the same
molecular weight as RBM5 even in GLC20 cells, making them unsuitable for use in RIP-Seq
experiments. See Figure S3 full blots of loading controls.
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the Reactome FI Network plugin, as the GSAASeq program is designed
specifically for RNA-Seq data. Using Reactome, we found 68 pathways with an
FDR < 8% (Table 5), many involved in gene expression and mRNA splicing/
metabolism. Interestingly, there was an enrichment of RBM5 targets in the EGFR
pathway (Fig. 7), as well as many cell cycle pathways and the ‘Apoptosis induced
DNA fragmentation’ pathway (Fig. 8), supporting our RNA-Seq results and
suggesting that RBM5 may play a direct role in regulating the cell cycle and
apoptosis in SCLC cells.
It is interesting to note that of all the genes shown in our RNA-Seq experiments to
experience a significant change in alternative splicing upon RBM5 expression in T2
or C4 (Table 3 and Table 4), only one, ArfGAP with SH3 Domain, Ankyrin Repeat
and PH Domain (ASAP1), was identified as an RBM5 target in our RIP-Seq
experiments. This suggests that the effect of RBM5 expression on alternative
splicing largely results from downstream consequences of changes in RBM5
expression, as opposed to a targeted RBM5 interaction with the alternatively
spliced transcript.
Taken together, our RNA-Seq and RIP-Seq pathway analyses revealed that RBM5
directly influences many processes involved in the maintenance of a non-
transformed state, and this by means distinct from regulation of alternative
splicing.
[(Fig._6)TD$FIG]
Fig. 6. RBM5 RIP-Seq optimization and quality control. (A) Raw Western Blot data demonstrating
successful immunoprecipitation of RBM5. (B) Scatterplot representing expression of genes with FPKM
< 5000 in control and RBM5 RIP samples, respectively. All Western Blot ladder sizes are in kilodaltons
(kDa).
Article No~e00204
18 http://dx.doi.org/10.1016/j.heliyon.2016.e00204
2405-8440/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 5. RBM5 RIP-Seq results, showing top enriched pathways (FDRs below 8%), identified by
Cytoscape Reactome FI Plugin tool using the Reactome Pathway Database.
Reactome Pathway FDR
Nonsense-Mediated Decay (NMD) 5.88E-05
NMD enhanced by the Exon Junction Complex 5.88E-05
Influenza Infection 6.67E-05
HATs acetylate histones 7.14E-05
Influenza Life Cycle 7.69E-05
Processing of Capped Intron-Containing Pre-mRNA 8.33E-05
GTP hydrolysis and joining of the 60S ribosomal subunit 9.09E-05
NMD independent of the Exon Junction Complex 1.00E-04
mRNA Splicing 1.00E-04
mRNA Splicing - Major Pathway 1.00E-04
Influenza Viral RNA Transcription and Replication 1.05E-04
Eukaryotic Translation Elongation 1.11E-04
L13a-mediated translational silencing of Ceruloplasmin expression 1.25E-04
3' -UTR-mediated translational regulation 1.25E-04
Eukaryotic Translation Initiation 1.67E-04
Cap-dependent Translation Initiation 1.67E-04
Cell Cycle, Mitotic 2.27E-04
Formation of a pool of free 40S subunits 2.38E-04
Translation 2.50E-04
Attenuation phase 2.61E-04
Metabolism of proteins 3.08E-04
Translation initiation complex formation 3.20E-04
Ribosomal scanning and start codon recognition 3.20E-04
Chromatin modifying enzymes 3.33E-04
Chromatin organization 3.33E-04
SRP-dependent cotranslational protein targeting to membrane 6.88E-04
Cellular responses to stress 6.97E-04
Cell Cycle 7.10E-04
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S 7.33E-04
Mitochondrial biogenesis 7.35E-04
Viral mRNA Translation 7.59E-04
Peptide chain elongation 7.59E-04
Eukaryotic Translation Termination 7.59E-04
HSF1-dependent transactivation 9.14E-04
Organelle biogenesis and maintenance 1.00E-03
Gene Expression 1.00E-03
(Continued)
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2.6. Functionally, RBM5 inhibits cell growth and sensitizes cells
to cisplatin–mediated apoptosis
In other cancer cell lines, RBM5 has been shown to regulate the cell cycle and
modulate responses to apoptogenic stimuli (Kobayashi et al., 2011; Oh et al., 2006;
Rintala-Maki and Sutherland, 2004). Since we identified ‘Cell Cycle’ (Fig. 3C and
Table 5. (Continued)
Reactome Pathway FDR
Calnexin/calreticulin cycle 1.84E-03
Deadenylation of mRNA 2.11E-03
G2/M Transition 2.21E-03
Transcriptional activation of mitochondrial biogenesis 2.53E-03
Mitotic G2-G2/M phases 2.81E-03
N-glycan trimming in the ER and Calnexin/Calreticulin cycle 4.26E-03
EGFR downregulation 4.67E-03
Cellular response to heat stress 6.91E-03
ISG15 antiviral mechanism 7.04E-03
Antiviral mechanism by IFN-stimulated genes 7.04E-03
M Phase 7.45E-03
Formation of the ternary complex, and subsequently, the 43S complex 1.07E-02
Activation of gene expression by SREBF (SREBP) 1.11E-02
Deadenylation-dependent mRNA decay 1.11E-02
Regulation of PLK1 Activity at G2/M Transition 1.12E-02
Regulation of cholesterol biosynthesis by SREBP (SREBF) 1.84E-02
Cellular Senescence 2.37E-02
Mitotic Anaphase 2.40E-02
Mitotic Prometaphase 2.51E-02
Mitotic Metaphase and Anaphase 2.55E-02
Resolution of Sister Chromatid Cohesion 3.48E-02
Centrosome maturation 4.44E-02
Recruitment of mitotic centrosome proteins and complexes 4.44E-02
Loss of Nlp from mitotic centrosomes 6.15E-02
Loss of proteins required for interphase microtubule organization from the centrosome 6.15E-02
mRNA Splicing − Minor Pathway 7.52E-02
MicroRNA (miRNA) biogenesis 7.79E-02
Initiation of Nuclear Envelope Reformation 7.79E-02
Nuclear Envelope Reassembly 7.79E-02
Recycling of eIF2:GDP 7.79E-02
Apoptosis induced DNA fragmentation 7.79E-02
Activator of DNA fragmentation factor 7.79E-02
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D) and ‘Apoptosis’ (Table 1) as pathways likely influenced by the differentially
expressed genes in T2 and C4, respectively, we decided to validate our sequencing
data by carrying out functional studies.
To see if and how RBM5 affects the cell cycle in SCLC, we performed a
proliferation and membrane integrity assay using our GLC20 cells and sublines. As
shown in Fig. 9A, C4 had significantly decreased cell numbers, relative to the
[(Fig._7)TD$FIG]
Fig. 7. RBM5 targets in the EGFR Signaling pathway. Network analysis results of RBM5 targets
(identified by RIP-Seq) in a portion of the EGFR Signaling pathway. Purple indicates that the gene was
identified as an RBM5 target.
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vector control, by day six, while membrane integrity was unaffected (Fig. 9B).
This suggests that when RBM5 levels are high, such as in C4, RBM5 slows cell
cycle progression in untreated SCLC cells, thereby promoting a non-transformed
state, a result that supports our RNA-Seq findings.
In North America, due to the usual late stage diagnosis and consequent metastasis,
SCLC tumors are not commonly resected, but rather treated with a combination of
platinum-based agents such as cisplatin or carboplatin, and the topoisomerase
inhibitor etoposide (Gaspar et al., 2012; Jackman and Johnson, 2005; Johnson
et al., 2014; Travis et al., 2004). Initially, the patient may show a complete
response to the treatment, but most will relapse as the cancer develops resistance
[(Fig._8)TD$FIG]
Fig. 8. RBM5 targets in the Apoptotic Execution Phase pathway. Pathway analysis results of RBM5
targets (identified by RIP-Seq) in a portion of the Reactome Apoptotic Execution Phase pathway.
Purple indicates that the gene was identified as an RBM5 target.
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(Jackman and Johnson, 2005). Understanding how SCLC cells develop resistance
to these drugs is thus of great importance. We therefore included a platinum-based
treatment in our functional analysis, and determined the effects of RBM5
expression on SCLC cells’ response to the drug. Cisplatin was our drug of choice
since, as demonstrated in Fig. 2, GLC20 cells are already quite resistant to
cisplatin, making them a good model for a drug sensitization study. Interestingly,
RBM5 overexpression in the cisplatin-resistant NSCLC cell line A549 reduced
resistance to cisplatin, manifesting as increased cisplatin-induced apoptosis (Li
et al., 2012), thus we expected that RBM5 expression in our SCLC cell line would
have a similar effect.
The GLC20 parental cell line and sublines were treated with 1 μM cisplatin, and
cell proliferation and membrane integrity assessed. Both T2 and C4 cells showed
significantly decreased cell numbers, relative to the vector control, following 10
days of cisplatin exposure (Fig. 9A), and a significant decrease in membrane
[(Fig._9)TD$FIG]
Fig. 9. Effect of RBM5 expression +/− cisplatin on cell proliferation and membrane integrity. (A and
B) GLC20 sublines were left untreated, or exposed to either a saline control or 1.0 μM cisplatin and cell
numbers (A) or membrane integrity (B) monitored every other day by cell counting using a
hemocytometer. Average of three biological replicates carried out in technical triplicate with standard
error is displayed. A two-way ANOVA was performed between pcDNA3 and the other sublines, with
Bonferroni post-hoc analysis. (C) GLC20 subline membrane integrity was monitored after eight days of
exposure to various concentrations of cisplatin. Results represent the average of three biological
replicates performed in technical triplicate with standard error using the calculated average EC50
(calculated from Graphpad Prism 5, ‘non-linear fit − log(inhibitor) vs response (3 parameters)’). Graph
represents the average EC50 of three biological replicates. One-way ANOVA was performed with
Tukey post-hoc analysis, between sublines, with *p < 0.05, **p < 0.01, ***p < 0.001 and ****p <
0.0001.
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integrity by day four (Fig. 9B). In addition, the IC50 for cisplatin in both of the
RBM5 expressing sublines was significantly lower than the vector control
(Fig. 9C).
To determine if the decreased membrane integrity observed in T2 and C4 upon
cisplatin treatment was due to increased apoptosis, we examined apoptotic marker
expression using fluorescence microscopy. When cells were untreated, no
significant change in the level of cell death was observed between sublines
(Fig. 10A and B), consistent with our membrane integrity results (Fig. 9B).
Following four days of exposure to 5 μM cisplatin, however, significantly more
[(Fig._10)TD$FIG]
Fig. 10. Effect of RBM5 expression +/− cisplatin on apoptosis. GLC20 sublines were left untreated (A,
B) or treated with 5 μM cisplatin (C, D, E, F) and collected after four days for fluorescence microscopy
(A, C) or PARP cleavage analysis (E, F). Average number of Live (only Hoechst/blue), Early Apoptosis
(condensed Hoechst/blue and/or Annexin-V/green) and Late Apoptosis/Necrosis (7-AAD/Red)
fluorescence microscopy events from three biological replicates, each with 10 different fields of view,
with standard error, for the untreated cells (B) and 5 μM cisplatin (D). (E) A representative Western blot
for PARP cleavage, in the cisplatin-treated samples, with (F) densitometric analysis of ‘percent 89kDa
PARP cleavage product’ [(89kDa cleaved PARP/total PARP)x100], with standard error, from three
biological replicates, using the AlphaEase FC, ‘1D-Multi’ analysis tool. One-way ANOVA was
performed with Tukey post-hoc analysis, between sublines, with *p < 0.05 and ***p < 0.001. See
Figure S4 for full blots of E.
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cells were observed in both early and late stage apoptosis in the C4 cells, compared
to the vector control (Fig. 10C and D). Furthermore, Poly(ADP-Ribose)
Polymerase (PARP) cleavage was significantly increased in the C4 cells, following
cisplatin treatment (Fig. 10E and F). (An insignificant increase in cisplatin-
mediated apoptosis was observed in the T2 subline, by Western blot (Fig. 10E and
F) and fluorescence microscopy (Fig. 10C and D)).
These results suggest that RBM5 expression does in fact sensitize cells to
cisplatin’s pro-apoptotic effects, being in line with our RNA-Seq and RIP-Seq data,
which suggest that RBM5 influences the regulation of apoptotic pathways.
2.7. In cisplatin-treated GLC20 cells, RNA-Seq shows that 7% of
the transcriptome is differentially expressed by RBM5, and that
DSG2 and ATP11C are the most altered genes, potentially
driving the observed downstream effects of RBM5 expression
Having demonstrated that RBM5 expression can significantly influence a SCLC
cell line’s response to cisplatin, at least in terms of cell proliferation, membrane
integrity and apoptosis, we decided to examine this influence on a more global
level, by performing RNA-Seq on the cells treated with 5 μM cisplatin for four
days.
We identified 1,797 differentially expressed genes in the control vs. T2 group (7%
of genes examined), 1,225 in the control vs. C4 group (4.7%), with 457 genes being
common to both groups. Fewer differentially expressed genes in C4 compared to
T2 was an unexpected finding, based on our RNA-Seq data from the untreated
samples, and was possibly due to the increased rate of apoptosis in the high RBM5
expressing cells, limiting the measurable effect on gene expression by RNA-Seq.
The most highly upregulated genes common to treated T2 and C4 cells were
Protein Phosphatase 1 Regulatory Inhibitor Subunit 1A (PPP1R1A) and Makorin
Ring Finger Protein 3 (MKRN3). MKRN3 has been shown to be important to
development, particularly the onset of puberty (Abreu et al., 2013), which is in line
with previously identified RBM5 functions, as described above.
The most highly downregulated genes common to treated T2 and C4 include (a)
Translocase of Outer Mitochondrial Membrane 40 Like (TOMM40L), which is a
component of the outer mitochondrial membrane translocase, and thus influences
many mitochondrial processes (Humphries et al., 2005), (b) ATPase Phospholipid
Transporting 11C (ATP11C), whose cleavage (or downregulation) is required for
phosphatidylserine exposure and consequent phagocytosis during apoptosis
(Segawa et al., 2014; Yabas et al., 2016), and (c) Desmoglein 2 (DSG2), a
ubiquitously expressed cell adhesion protein upregulated in many epithelial-
derived cancers (Brennan and Mahoney, 2009; Harada et al., 1996; Kurzen et al.,
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2003) and shown to promote cell cycle progression and apoptosis-resistance
(Brennan et al., 2007; Gupta et al., 2015). These three genes thus play an important
role in cell survival, and it may be via their downregulation that RBM5 slows
SCLC growth and sensitizes them to cisplatin-mediated apoptosis. Interestingly,
ATP11C and DSG2 are also significantly downregulated in untreated T2 and C4
cells, suggesting that cisplatin treatment may complement/enhance the effect of
RBM5’s expression on SCLC.
FIDEA analysis using the KEGG database showed that no pathways were
downregulated and two pathways were significantly enriched in our control vs. T2
group; ‘Axon guidance’ (Benjamini value of 2.02 × 10−6) and ‘Retrograde
endocannabinoid signaling’ (Benjamini value of 4.22 × 10−4). In our control vs. C4
group, only ‘Axon guidance’ was significantly enriched (Benjamini value of 9.44
× 10−3). These results are very interesting since axon guidance is involved in the
establishment of a transformed state (Chedotal et al., 2005), and was also
significantly altered in our untreated T2 and C4 samples, suggesting cisplatin
treatment may complement this particular RBM5 function. Absence of ‘Retrograde
endocannabinoid signaling’ in the control vs. C4 group might explain the presence
of fewer differentially expressed genes in the C4 vs. T2 group.
Using the GSAASeqSP program with the MSigDB Hallmark gene set, we
identified 24 enriched gene sets with FDRs < 10% between cisplatin-treated
control and T2, and 18 between control and C4, of which 16 were common
between both (Table 6). It is important to note that only 12 MSigDB Hallmark
gene sets were identified as significantly enriched in our untreated control vs. T2
samples, and 17 in untreated control vs. C4. The greater number of significantly
changed pathways in the treated samples, but with fewer genes differentially
expressed overall, suggests once again that cisplatin directs the effect of RBM5’s
expression to particular genes. Noticeably, 10 of the 16 enriched pathways that
were common to the T2 and C4 cisplatin treated sample sets were also enriched in
the untreated C4 samples at a FDR of 10% or lower, demonstrating that cisplatin
exposure did not totally alter the influence of RBM5 expression on the SCLC cell’s
transcriptomes.
The ‘Apoptosis’ gene set was one of the significantly enriched pathways identified
by GSAASeqSP in cisplatin-treated T2 and C4 samples, compared to control,
which is in line with the functional work presented herein (Fig. 9 and Fig. 10). In
cisplatin-treated T2 samples, 72 genes from this ‘Apoptosis’ gene set were
significantly enriched compared to control, and 58 in C4. Of these genes, 35 were
common between both groups (Fig. 11), suggesting that many of the same
apoptotic pathways were significantly affected in both samples. T2 had 37
uniquely differentially expressed genes while C4 had 23, suggesting that a wider
range of apoptotic processes were significantly affected by cisplatin in T2.
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Interestingly, SMAD7 was the top enriched gene common to both T2 and C4
cisplatin-treated samples (third most enriched gene in both samples). Since
SMAD7 has been shown to sensitize lung cells to cisplatin-mediated apoptosis
(Jeon et al., 2012), it may be an important mediator of RBM5’s sensitizing effect
regarding cisplatin-induced promotion of apoptosis.
To further investigate which specific apoptotic processes were enriched in our
cisplatin-treated samples, we analyzed the enriched genes from the ‘Hallmark
Apoptosis’ gene set, as identified by GSAASeqSP, using the Reactome plug-in for
Cytoscape (as described for RIP-Seq samples) (Fig. 12). These results confirmed
that a wider range of apoptotic processes were influenced in the T2, compared to
the C4, population; the ‘Intrinsic pathway for apoptosis’ and the ‘Apoptotic
execution’ phase were significantly enriched in both cisplatin-treated T2 and C4
samples, however ‘Caspase-8 activation’ and the ‘Extrinsic pathway’ were only
significantly enriched in T2 (Fig. 13 and Fig. 14). These T2-specific pathways are
part of the early steps of apoptosis, suggesting that many cells in the cisplatin-
Table 6. Altered gene sets with FDRs below 10% between both cisplatin-treated
control and T2, and control and C4 samples, respectively, as determined by
GSAASeq analysis with the MSiDB Hallmark gene set using the samples’ RNA-
Seq results. Ranked based on FDR value in control vs. C4 analysis.
Control vs. T2 Control vs. C4
Gene set p-value FDR p-value FDR
TGFβ signaling 0.0 0.05 0.0 03
Notch signaling 0.2 0.07 0.0 0.04
EMT 0.0 0.00 0.0 0.04
Myogenesis 0.0 0.05 0.0 0.04
Estrogen response early 0.0 0.04 0.0 0.05
Coagulation 0.0 0.04 0.0 0.05
Angiogenesis 0.0 0.00 0.1 0.07
Androgen response 0.0 0.05 0.0 0.07
UV response down 0.0 0.05 0.0 0.08
Apoptosis 0.0 0.04 0.0 0.08
Inflammatory response 0.0 0.03 0.0 0.08
Estrogen response late 0.0 0.03 0.0 0.08
KRAS signaling up 0.0 0.04 0.0 0.08
TNFα signaling via NFκB 0.0 0.03 0.0 0.08
IL2 STAT5 signaling 0.0 0.04 0.0 0.08
Apical junctions 0.0 0.04 0.0 0.09
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treated T2 population were beginning the apoptotic process, but had not yet fully
committed to programmed cell death. The cisplatin-treated C4 population,
however, had a significant enrichment of the ‘Intrinsic pathway for apoptosis’
subgroups ‘Activation of BH3-only proteins’ and ‘BH3-only proteins associate
with and inactivate anti-apoptotic BCL-2 members’. These BH3-only proteins are
essential for apoptosis (Shamas-Din et al., 2011).
[(Fig._11)TD$FIG]
Fig. 11. Expression of apoptosis-related genes in cisplatin treated samples. Adapted GSAASeqSP blue-
pink o’gram representing the expression changes of core enriched genes from the MSigDB Hallmark
Apoptosis gene set in cisplatin treated control vs. T2 and control vs. C4. Blue indicates decreased
expression compared to control, whereas red indicates increased expression compared to control. Genes
listed in alphabetical order.
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This in-depth pathway analysis shows that relatively low levels of RBM5 are able
to sensitize SCLC cells to cisplatin-mediated apoptosis by influencing changes in
the expression of genes involved in early apoptosis events. At relatively higher
levels of RBM5 expression, this effect on cell death levels is detectable via
fluorescent microscopy (Fig. 10C). These results suggest that the level of RBM5
expression in lung tumors could predict response to cisplatin.
Taken together, our results show that RBM5 can functionally (a) influence cell
cycle progression in untreated and cisplatin-treated SCLC cells (potentially via
decreased DSG2 expression), and (b) sensitize cisplatin-treated SCLC cells to
cisplatin-mediated apoptosis (potentially via decreased DSG2 and ATP11C
expression, as well as increased SMAD7 expression). These findings reinforce
the importance of RBM5 expression to SCLC cisplatin-sensitivity and highlight the
potential of RBM5 as a response marker for this chemotherapy treatment in SCLC.
In fact, a recent publication suggested that RBM5 gene therapy might be considered
for NSCLC and that RBM5 might be a predictive marker to indicate the potential
success of using cisplatin on a particular lung cancer (Li et al., 2012): our results
support this suggestion and extend it to SCLC.
It is important to note that RBM5 expression was recently shown to increase
autophagy levels in a NSCLC cell line (Su et al., 2016), therefore, we also
examined the expression of autophagy markers BCL2, NF-κB, LC-3, LAMP1 and
BECLIN1 in the RNA-Seq data from our cisplatin-treated C4 cells. Only NF-κB,
however, was significantly differentially expressed compared to control; thus,
[(Fig._12)TD$FIG]
Fig. 12. Enriched ‘Programmed cell death’ pathways in cisplatin treated samples. Diagram illustrating
the Reactome ‘Programmed cell death’ pathways enriched with an FDR below 10% in cisplatin-treated
control vs. T2 (purple), control vs. C4 (blue) or control vs. T2 and C4 (orange).
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autophagy does not seem to be a mechanism by which RBM5 expression influences
membrane integrity in cisplatin-treated SCLC cells.
2.8. In patient samples, RNA-Seq shows that RBM5 expression is
reduced by 50% in tumors and that similar pathways are
disrupted
To determine if the RBM5-influenced pathways that we identified in vitro were
also influenced in vivo, we carried out RNA-Seq on primary tissue specimens.
SCLC tumor resection is not routinely carried out in North America, but we did
obtain two fresh frozen paired non-tumor and SCLC specimens. Transcriptome
sequencing and analysis were performed on all four specimens.
[(Fig._13)TD$FIG]
Fig. 13. Gene enrichment for apoptosis-related pathways in cisplatin-treated T2 samples. Reactome
diagram for ‘Death receptor signaling’ (A) and ‘Caspase-8 activation by cleavage’ (B). Differentially
expressed genes between cisplatin treated control vs. T2 are presented in purple.
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[(Fig._14)TD$FIG]
Fig. 14. ‘Apoptotic execution phase’ gene enrichment in cisplatin-treated samples. Differentially
expressed genes between cisplatin treated control vs. T2 (A) or control vs. C4 (B) are presented in
purple in a portion of the Reactome ‘Apoptotic execution phase’ pathway.
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We identified 14,346 and 14,119 genes differentially expressed between both non-
tumor and tumor pairs, respectively, thus slightly more than half of the genes
studied. Interestingly 12,116 (∼85%) of these differentially expressed genes were
common to both paired groups, suggesting that, contrary to what one might expect
in a tumor, a fairly conserved mechanism is involved in the evolution of SCLC, a
favorable feature for treatment development.
RBM5 expression was very similar in both non-tumor specimens, and decreased by
half in the corresponding tumor specimens; from 40.43 FPKM to 18.55 FPKM in
the first patient specimens, and from 39.00 FPKM to 22.30 FPKM in the second
patient specimens. This significant decrease of approximately 50% suggests that
loss of heterozygosity (LOH) may be the cause of decreased RBM5 expression in
SCLC. In fact, LOH of a portion of 3p21.3 close to RBM5 has been observed in
over 95% of SCLC and 70% of NSCLC (Ji et al., 2005; Kok et al., 1997; Lerman
and Minna, 2000; Sutherland et al., 2010; Wei et al., 1996; Wistuba et al., 2000). It
is important to note that the RBM5 expression values in the non-tumor samples are
very similar to that of T2 (58.26 FPKM), thus lending physiological relevance to
our in vitro model.
Using FIDEA with the KEGG database, 34 pathways were shown to be
significantly differentially regulated in both tumor specimens compared to their
respective non-tumor control (Table 7). GSAASeqSP with MSigDB Hallmark
gene set also showed that many gene sets were enriched; 18 in the first patient
sample, and 26 in the second, with 15 gene sets being common between both
sample pairs (Table 8). Differentially expressed pathways, as determined by both
FIDEA and GSAASeqSP, included almost all of the RBM5-influenced pathways
identified above, including many transformation-associated pathways, notably
‘Pathways in cancer’, ‘Cell cycle’, ‘Small cell lung cancer’, ‘Axon guidance’, ‘p53
signaling’, ‘TNFα signaling via NFĸB’ and ‘Apoptosis’. This high level of
correlation between significantly differentially expressed pathways in our SCLC
patient samples and the RBM5 expressing cell lines supports, once again, our
conclusion that RBM5 plays a role influencing pathways that are very important to
the transformed state of SCLC cells.
3. Conclusion
Lung cancer is the leading cause of cancer-related deaths worldwide. The most
aggressive form of lung cancer is SCLC, with a staggering 95% of diagnosed
patients succumbing to the disease (Govindan et al., 2006). This high mortality rate
clearly demonstrates the need for more effective screening techniques and
treatment options. Our results show, for the first time, that RBM5 expression is
important to the maintenance of the non-transformed state of lung cells, and that
this is accomplished via direct regulation of the cell cycle and apoptosis, and
Article No~e00204
32 http://dx.doi.org/10.1016/j.heliyon.2016.e00204
2405-8440/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 7. Significantly altered pathways between both patient SCLC tumor/non-tumor pairs as determined
by FIDEA analysis with KEGG database (using the samples’ RNA-Seq results). Pathways are listed based
on significance of enrichment in the first patient sample.
Pathway Non-tumor/tumor pair 1
(Benjamini value)
Non-tumor/tumor pair 2
(Benjamini value)
Pathways in cancer 1.23E-12 6.36E-14
Cell cycle 9.75E-10 1.99E-10
Regulation of actin cytoskeleton 3.03E-06 3.06E-07
Focal adhesion 3.03E-06 5.50E-08
Chronic myeloid leukemia 2.60E-05 7.09E-10
p53 signaling pathway 2.60E-05 2.23E-06
Fc gamma R-mediated phagocytosis 2.64E-05 3.95E-06
Neurotrophin signaling pathway 1.11E-04 3.68E-10
Colorectal cancer 1.64E-04 5.82E-08
Bacterial invasion of epithelial cells 1.82E-04 1.22E-06
Pancreatic cancer 1.82E-04 1.22E-06
Phosphatidylinositol signaling system 2.81E-04 4.93E-04
Prostate cancer 3.58E-04 1.58E-06
Small cell lung cancer 6.00E-04 3.74E-04
Axon guidance 1.04E-03 1.16E-06
Leukocyte transendothelial migration 1.37E-03 3.74E-04
Acute myeloid leukemia 1.73E-03 1.27E-05
Renal cell carcinoma 1.79E-03 3.74E-04
Inositol phosphate metabolism 2.29E-03 1.39E-02
Ubiquitin mediated proteolysis 4.01E-03 6.36E-04
Salmonella infection 4.20E-03 1.68E-02
Adherens junction 4.20E-03 9.09E-06
DNA replication 4.20E-03 1.39E-02
T cell receptor signaling pathway 7.53E-03 2.78E-05
mTOR signaling pathway 8.57E-03 4.60E-04
Base excision repair 1.69E-02 1.26E-02
Glioma 1.72E-02 1.31E-04
Shigellosis 1.76E-02 2.25E-05
B cell receptor signaling pathway 1.78E-02 8.53E-04
MAPK signaling pathway 1.78E-02 4.77E-02
ErbB signaling pathway 1.97E-02 1.57E-05
Endometrial cancer 2.21E-02 1.57E-05
N-Glycan biosynthesis 3.89E-02 1.23E-02
Chemokine signaling pathway 4.69E-02 1.35E-04
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indirect regulation of overall cell death, angiogenesis, and cell adhesion.
Functional studies confirmed that RBM5 expression in SCLC (1) slowed the cell
cycle, and (2) decreased membrane integrity, partially via increased apoptosis
when cells were treated with the chemotherapy agent cisplatin. Therefore,
decreased RBM5 expression, as is observed in 95% of SCLC, may be a critical step
in the establishment of this disease. In a clinical setting, downregulation of RBM5
expression could be a novel biomarker for the determination of SCLC risk.
Therapeutic options involving RBM5 and/or direct targets, or pathways altered by
RBM5 expression, may also be very fruitful avenues to pursue. Furthermore, due to
the significant sensitization RBM5 expression had on cisplatin-treated samples,
RBM5 expression could be a valuable predictive aid for assessing how a patient
may respond to this chemotherapy. Ultimately, this work demonstrates, for the first
time, the importance of RBM5 to SCLC. Our results present a stepping-off point
for additional targeted functional work.
Table 8. Altered gene sets with FDRs below 1% in both patient SCLC tumor/non-
tumor pairs, as determined by GSAASeqSP analysis with the MSigDB Hallmark
gene set (using the samples’ RNA-Seq results). Pathways are listed based on FDR
in the first patient sample.
Non-tumor/tumor
pair 1
Non-tumor/tumor
pair 2
Gene set p-value FDR p-value FDR
TNFα signaling via NFĸB* 0.0 0.0 0.0 0.0
IL6 JK STAT3 signaling* 0.0 0.0 0.0 0.0
G2M checkpoint 0.0 0.0 0.0 0.0
Estrogen response late* 0.0 0.0 0.0 0.0
Interferon γ response 0.0 0.0 0.0 0.0
E2F targets 0.0 0.0 0.0 0.0
EMT* 0.0 0.0 0.0 0.0
Inflammatory response* 0.0 0.0 0.0 0.0
KRAS signaling up* 0.0 0.0 0.0 0.0
Pancreas β cells* 0.0 0.0 0.0 0.0
UV response down* 0.0 0.01 0.0 0.0
Interferon α response* 0.0 0.01 0.0 0.01
IL2 STAT5 signaling* 0.0 0.01 0.0 0.0
Apoptosis* 0.0 0.01 0.0 0.0
Coagulation* 0.0 0.01 0.0 0.0
* Beside a gene set name indicates it’s enrichment in untreated control vs. C4 samples, at an FDR <
10%.
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4. Materials & methods
4.1. Cell culture
SCLC GLC20 cells were a kind gift from the late Dr. Charles Buys from the
University of Groningen (Groningen, Netherlands). GLC20 cells and sublines
pcDNA3, T2 and C4 were maintained in RPMI 1640 (Gibco, Life Technologies)
supplemented with 10% fetal bovine serum (FBS, Gibco) (termed complete
media), with the addition of 0.1 mg/mL G418/Geneticin (Gibco) for pcDNA3, T2
and C4 sublines. Cells were maintained at 37 °C with 5% CO2 in a humidified
chamber.
4.2. Southern blotting
Genomic DNA was isolated by spooling, following overnight incubation in Tail
Buffer (1% SDS, 0.1 M NaCl, 0.1 M EDTA, 0.05 M Tris, pH8), treated with 50 μg/
ml of RNase A (Amersham Biosciences) and cleaned using Qiagen Genomic-tip
100/G columns, following the manufacturer’s instructions. The Southern blot was
prepared and probed as previously described (Rintala-Maki and Sutherland, 2009).
The RBM5 probe was prepared using the PROSTAR HF single tube RT-PCR
System (Stratagene), labelling with radioactive phosphate, and cleaning with a G25
sepharose column, following manufacturer’s instructions.
4.3. GLC20 apoptosis profiles
GLC20 cells were diluted 1:2 in a 24 well plate 24 h before treatment. The
following day, cells were treated with cisplatin (Sigma-Aldrich) dissolved in
dimethyl sulfoxide (DMSO) and/or etoposide (Sigma-Aldrich) dissolved in
DMSO. Cells were then incubated for varying amounts of time, as shown in
Fig. 2, at 37 °C in a 5% CO2 humidified incubator.
4.4. Western blotting
Primary antibodies used were rabbit anti-RBM5 LUCA-15-UK (non-commercially
available) (1:2,500 or 1:5,000) (Sutherland et al., 2000), rabbit anti-human PARP
(1:1,500–1:2,000, C2-10: BD Pharmingen) and mouse anti-α-tubulin primary
antibody (1:10,000, sc-8035, Santa Cruz Biotechnology, Inc.). Secondary
antibodies used were goat anti-mouse HRP-conjugated secondary antibody
(1:10,000, sc-2005; Santa Cruz Biotechnologies Inc.) or goat anti-rabbit HRP-
conjugated secondary antibody (1:10,000, sc-2004; Santa Cruz Biotechnologies
Inc.). Protein was exposed using Amersham ECL Western blotting detection
reagents (GE-Healthcare) to Amersham Hyperfilm (GE-Healthcare). Film was then
developed using a SRX-101A medical film processor (Konica Minolta Medical
and Graphic Inc.).
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4.5. Establishment of stable RBM5-expressing GLC20 sublines
GLC20 sublines were established following DMRIE-C transfection with pcDNA3 or
pcDNA3.RBM5, and stable selection with G418 at 1.0 mg/ml in soft agar for 120
days. Detailed protocol is as follows; Cells were passaged 1:2, 24–48 h prior to
transfection. 10 ml of cell culture (∼ 2 × 106 cells) were used in each transfection,
with 24 μl DMRIE-C (Life Technologies) and 8 μg total DNA (pcDNA3 or pcDNA3.
RBM5). DMREI-C and DNA were incubated for ∼30 min prior to cell addition. The
cell/DMREI-C/DNA mix was then incubated at 37 °C and 5% CO2 for 4 h, and the
transfection terminated by adding serum. Transfected cells were selected using G418,
at a concentration of 1.0 mg/ml, a concentration previously determined to kill all
untransfected cells by seven days. Following transfection, a clonal population of cells
was established following plating in soft agar, as previously described (Longthorne
and Williams, 1997). Four empty vector transfected clones and five RBM5
transfected clones were picked following 36 days of G418 selection in soft agar.
After 120 days of continuous growth in G418 (following the first dilution of 10 ml of
stably transfected cells, the selection reagent concentration was reduced from 1.0 to
0.1 mg/ml), only two of the five RBM5-transfected clones survived. One of these,
designated C4, as well as one empty vector control clone, were used in subsequent
studies. A second transfectionwas carried out in order to generate a pooled population
of RBM5-transfected cells (eventually designated T2).
4.6. RNA extraction
GLC20 RNA samples were isolated using Tri-Reagent (BioCan Scientific). For RNA
templates used in PCR, reverse transcription was performed as previously described
(Loiselle and Sutherland, 2014). In regards to the Ontario Tumour Bank (OTB) tissue
samples, 20 mg of tissue was cut with a sterile blade from fresh frozen tissue
specimens that had been stored at−80 °C. The 20mg tissue piece was transferred to a
Bessman Tissue Pulverizer (VWR) that had been placed in liquid nitrogen for 10min.
Once the pulverizer was secured, a hammer was used to smash the tissue until it
obtained a powder-like consistency. Powdered tissue was transferred to a solution
containing Buffer RLT (Qiagen) and 0.14 mM β-mercaptoethanol, and homogenized
using a Polytron PT 1300 D Homogenizer (Kinematica). The lysate was centrifuged
for 3min at 17000 x g to pellet tissuematter that did not homogenize. Supernatant was
transferred to an Allprep DNA/RNA/Protein Mini Kit spin column (Qiagen) and
RNA was extracted according to manufacturer’s instructions. It is important to note
that RNA was extracted from two 20 mg pieces of tissue, and combined.
4.7. PCR
RBM5 genomic DNA PCR was performed using Gen1E2Fc (exon 2: 5′-
CTTCAGTGGGACAATGGGTTCAGA-3′) and Gen2E3I2R (exon 3/intron 2:
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5′-CCACTACGCTCTGTTCTACTCACTCTGCCA-3′) primers, with the follow-
ing PCR amplification program 95 °C 5 min, [95 °C 30 s/65 °C 30 s/68 °C 2 min]
(40 cycles), 68 °C 10 min. RBM5 RT-PCR was performed using LU15(2) (exon 4)
and LU15(3) (exon 8) primers, as previously described (Sutherland et al., 2000).
GAPDH was amplified using GAPDH-F (exon 6: 5′ AACACAGTCCATGC-
CATCAC 3′) and GAPDH-R (exon 7: 5′ TCCACCACCCTGTTGCTGTA), with
an annealing temperature of 58−59 °C and 25–35 amplification cycles. PCR and
product visualization were carried out as previously described (Loiselle and
Sutherland, 2014). Approximate primer locations shown in Fig. 1G.
4.8. RNA-Sequencing and analyses
Extracted RNA was sent to the Donnelly Sequencing Centre (Toronto, Canada) for
Illumina TruSeq stranded mRNA library preparation with Ribozero depletion,
followed by paired-end high throughput sequencing using the Illumina HiSeq 2500
platform.
All four untreated GLC20 subline samples were multiplexed together during
sequencing, as were the four cisplatin-treated samples. It is important to note that
there were some differences between sample preparation and sequencing for
cisplatin treated and untreated RNA-Seq samples; (1) untreated samples were
DNase treated prior to sequencing, (2) reads were 100 bp for untreated samples and
125 bp for cisplatin treated samples, and (3) untreated samples were sequenced in
duplicate (multiplexed on each of two paired-end lanes), while treated samples
were not sequenced in duplicate. Due to the longer read length for the cisplatin
treated samples and overall higher output, however, similar depth was achieved for
treated and untreated samples. Nonetheless, we only ran analysis within the treated
and untreated groups, and compared the outputs, so as to not potentially introduce
sequencing biases into our analyses. All four OTB specimens (two paired tumor
and non-tumor specimens) were also multiplexed and sequenced in duplicate.
Transcriptome sequencing data quality was verified by FastQC (Babraham
Bioinformatics, http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/). All speci-
mens had quality score distributions over all sequences above 37 (on a phred 33
quality scale). Primers and adapters used for sequencing were then removed using
cutadapt version 1.4.2 (Martin, 2011) using a quality cut-off of 26, as
recommended (Del Fabbro et al., 2013). Following trimming, data quality was
verified using FastQC. Trimmed reads were analyzed using the Tuxedo suite tools
as follows: (1) TopHat 2.0.11 (Kim et al., 2013) was used to align reads to the
human reference genome USCS hg19, (2) Cufflinks 2.1.1 (Trapnell et al., 2010)
was used to assemble the mapped reads and obtain FPKM values for each
investigated gene and isoform, (3) Cuffdiff 2.1.1 (Trapnell et al., 2013) was used to
investigate differential expression, and (4) CummeRbund (Trapnell et al., 2010)
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was used for visualization. Samtools (Li et al., 2009) and Picard (http://
broadinstitute.github.io/picard/) were used to assess mapping quality. For untreated
and treated GLC20 subline RNA-Seq samples, all samples had a very good
percentage of overall mapped reads and concordantly mapped paired reads, with
small standard deviations, permitting comparison between samples; in untreated
samples 94.06% ± 0.44% (SD) reads mapped, with 89.18% ± 0.28% being
concordant for both forward and reverse reads, and in the cisplatin treated samples
94.51% ± 0.87% reads were mapped, with 91.73 ± 1.07 of paired reads mapping
concordantly. Values were slightly lower for OTB patient specimens, as expected,
with 89.84 ± 3.08% reads mapped and 86.06 ± 2.87% concordant.
Prior to differential expression analysis, gene expression levels in both control
samples (parental GLC20 and GLC20.pcDNA3) were compared to see if they were
sufficiently similar to be combined into one experimental group; more replicates
provides greater power and accuracy in RNA-Seq experiments (Liu et al., 2014). In
fact, gene expression levels in both samples were very highly correlated (r =
0.9699 in untreated samples and r = 0.9813 in cisplatin treated samples), and thus
both controls were combined into one experimental group.
Pathway enrichment was investigated using the FIDEA (Functional Interpretation
of Differential Expression Analysis) program (D'Andrea et al., 2013) with the
KEGG database (Kanehisa and Goto, 2000; Kanehisa et al., 2016). Pathway
analysis was also performed using GSAASeqSP (Gene Set Association Analysis
for RNA-Seq with Sample Permutation) (Xiong et al., 2014) with the Molecular
Signatures Database (MSigDB) Hallmark gene set collection (Liberzon et al.,
2015). Since each program uses a different algorithm in their calculations, and each
gene set/functional interaction pathway set is curated separately, with different
foci, a broad view of affected cellular processes affected is gained, and results can
be compared between programs to identify the most robust changes.
For analysis of alternative splicing events in our RNA-Seq data, stringent
parameters were used in order to identify alternative splicing events: (1) the
expression of at least one alternative splice variant had to be significantly
upregulated, and (2) the expression of at least one other alternative splice variant
had to be significantly downregulated.
4.9. RNA immunoprecipitation followed by next generation
sequencing (RIP-Seq)
The basic RIP technique was carried out as previously described (Jain et al., 2011).
RNA associated with the immunoprecipitated samples was sequenced by the
Donnelly Sequencing Centre. Illumina TruSeq Stranded Total RNA library
preparation, including Ribozero Gold depletion, was performed along with random
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priming. Samples were sequenced in duplicate on the Illumina HiSeq 2500
platform, with each run being paired-ended, 125 bp reads.
RIP-Seq results were analyzed using the Tuxedo Pipeline (Trapnell et al., 2012),
with the same quality control steps used for RNA-Seq analysis. Using the FPKM
and log2-fold change values generated by Cuffdiff, the following inclusion criteria
were used to distinguish RBM5 targets from IP contaminants: the RBM5 RIP
sample target had to have (1) an FPKM value greater than one, (2) a log2-fold
change greater than one, and (3) a positive log2-fold change (meaning it was more
highly expressed than in the control RIP).
4.10. Cell counting, cell growth and cell death assays
Cells were plated at 10,000 per well in 96-well flat-bottom plates at a density of 50
cells/μL, in triplicate wells per treatment. Cells were left for 24 h at 37 °C with 5%
CO2 in a humidified chamber. After 24 h, the cells were treated with the following
conditions: left untreated, saline (0.9% NaCl in H2O) control, 1.0 μM cisplatin in
saline for 0, 2, 4, 6, 8 and 10 days, or 0.1, 0.5, 10.0 and 100.0 μM cisplatin for 4
and 8 days. Cisplatin (Sigma) was prepared, as previously described (Hall et al.,
2014), in saline at a concentration of 1.0 mg/mL. The cells were then counted
every other day by transferring cells to a 96-well Vee-bottom plate and subjecting
them to centrifugation at 500 x g for 5 min at 21 °C. The supernatant was discarded
and cells treated with 0.25% Trypsin-EDTA for 10 min at 37 °C with 5% CO2 in a
humidified chamber. Complete media was added to cells and they were subjected
to centrifugation at 500 x g for 5 min 21 °C. Cells were resuspended in complete
media and counted in a 1:1 ratio of cells in complete media and 0.2% nigrosin,
using a hemocytometer.
Live cells were counted as cells with intact membranes, characterized by a lack of
blue/purple nigrosin within the cells, and dead cells were counted as cells without
intact membranes, characterized by the presence of blue/purple nigrosin within the
cell. Live cell counts were used to monitor cell growth, relative to day 0 counts, and
the average of biological triplicates was plotted. A two-way ANOVAwas performed
with Bonferroni post-hoc analysis, comparing all subline cell growth to the pcDNA3
subline, calculated using Graphpad Prism 5. Percent intact membrane by nigrosin was
calculated using the following equation: percent intact membrane by nigrosin =
number of live cells divided by (number of live cells + number of dead cells) x 100.
Percent intact membrane by nigrosin for the 1.0 μM cisplatin values was also made
relative to saline controls, and the average of biological triplicates was plotted. A
two-way ANOVA was performed with Bonferroni post-hoc analysis, comparing all
subline results to the pcDNA3 subline, calculated using Graphpad Prism 5. Day
eight cisplatin results were made relative to the saline control for the calculation of
EC50 values. EC50 values were calculated using ‘log (inhibitor) vs. response
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(three parameters)’ on Graphpad Prism 5, and the average of biological triplicates
was plotted with the saline control represented at 10−10 M on the graphs. A one-
way ANOVA was performed with Tukey post-hoc analysis, comparing all sublines
to the pcDNA3 subline.
4.11. Apoptosis assays − Fluorescent microscopy
GLC20 cells and sublines were counted and 2.0 × 106 cells were plated in T75
flasks at a cell density of 50 cells/μL. After 24 h incubation at 37 °C with 5% CO2
in a humidified chamber, cells were either exposed to 5.0 μM cisplatin or left
untreated for 4 days. A fraction of cells was collected by centrifugation at 149 x g
for 7 min at 21 °C and supernatant was discarded, followed by centrifugation at
5,900 x g for 2 min at 21 °C, with supernatant discarded, and the pellet stored at
−80 °C for PARP cleavage analysis by Western Blot.
Another fraction of cells was used for apoptosis analysis by fluorescent microscopy.
These cells were subjected to centrifugation at 149 x g for 7 min at 21 °C, supernatant
was discarded, and the cells were treated with 0.25% Trypsin-EDTA for 10 min at 37
°C with 5% CO2 in a humidified chamber, to obtain a single cell suspension. Cells
were then washed two times in complete media and centrifuged at 500 x g for 5 min at
21 °C, with changes in media between each centrifugation, then counted in a 1:1 ratio
of cells in complete media and 0.2% nigrosin, using a hemocytometer. 0.5 × 106 cells
were resuspended at a 1000 cell/μL density in cold PBS for fluorescence analysis. If
fewer than 0.5 × 106 cells were counted, cells were adjusted to a smaller volume at a
1000 cell/μL density in cold PBS.
Before staining, cells were washed three times in cold PBS at 5,900 x g for 2 min at
21 °C, with changes in cold PBS between centrifugations, then resuspended in
Annexin V binding buffer (10 mM HEPES, 140 mM NaCl, and 2.5 mM CaCl2) at
a density of 1000 cells/μL. Cells were triple stained with 7-aminoactinomycin D
(7AAD) in DMSO, Annexin V-AlexaFlour® 488 conjugated, and Hoescht 33342
Nucblue® Live Cell Stain ReadyProbe Reagent (all Life Technologies) at 0.02 mg/
mL, 5 μL/100 μL, and 1 drop/500 μL concentrations, respectively, at 21 °C for 15
min in the dark. Cells were then washed three times in cold Annexin V binding
buffer at 5,900 x g for 10 min at 21 °C, then resuspended in 100 μL of cold PBS.
Samples were loaded into CytospinTM columns (Symport, VWR International) that
were pre-loaded with a microscope slide (VistaVision, VWR International). Cells
were centrifuged onto the microscope slides at 500 rpm for 2 min 21 °C in a
Shandon CytospinTM 4 cytocentrifuge (Thermo Scientific), rotor # 4127 0806
59930093. Samples on slides were air-dried, then fixed with 4% paraformaldehyde
(Sigma-Aldrich) in PBS at 21 °C in the dark for 10 min. Slides were washed
sequentially in three changes of PBS, then air-dried. 90% glycerol (Sigma-Aldrich)
in PBS was added to the samples and a No. 1 coverslip (VWR) was placed on top
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of the sample. The cover slip was sealed with nail polish and the slides stored at 4
°C in the dark until visualized (∼24 h later).
Cells were visualized using an Olympus 1 × 73 Microscope (Olympus Life
Sciences). Fluorphores were excited using Lumen Dynamics Xcite 120 LED
(Lumen Dynamics), Olympus LED PS and LBM laser systems (Olympus Life
Sciences). Fluorescence emission spectra were captured for Hoescht 33342 (Ex:
250 nm/Em: 461 nm), AlexaFlour® 488 (Ex: 495 nm/Em: 519 nm), and 7-AAD
(Ex: 546 nm/Em: 647 nm). In addition to fluorphores, cell morphology was
observed using phase contrast (images not included). Images of the stained cells
were captured using the Olympus DP80 camera (Olympus Life Sciences) and
CellSens Dimensions imaging software (Olympus Life Sciences). Images obtained
that were later counted underwent no post-production adjustments. Images
presented underwent post-production adjustments using the ‘Adjust Display’
function in the CellSens Dimensions imaging software. In brief, background colour
intensities were excluded from the images using the histogram tool. Colour
threshold intensity was then increased. These changes were applied to all the
images and at the same intensities.
Exposure times and gain were made constant during the imaging of each biological
replicate. Although exposure times varied, the Hoechst 33342 stain was exposed for
roughly 250milliseconds (ms), the Annexin V- Alex-Fluor 488 stain was exposed for
roughly 2 seconds (s) with a gain of 2X, and the 7-AAD stainwas exposed for roughly
800ms. All images were taken using a 40X objective lens. ‘Live’ events were defined
as cells with visually uncondensed nuclei, stained with Hoechst 33342, and lacking
green Annexin V stain or red 7-AAD stain. ‘Early Apoptosis’ events were defined as
cells that had either or both green Annexin V stain (indicative of phosphatidylserine
flipping) and condensed nuclei (condensed blue Hoechst 33342 staining). Lastly,
‘Late Apoptosis/Necrosis’ was defined as the loss of membrane integrity, which was
indicated by the presence of the red stain of 7-AAD (made purple/pink in images).
Three biological replicates were performed. For each biological replicate, the events
were totalled between ten fields of view counted. A minimum of 300 events was
counted per biological replicate. Values were then transformed to a percentage of the
total number of events that were counted, for each biological replicate. The average of
the three biological replicates was presented and one-way ANOVA was performed
between the sublines for each defined event. Tukey post-hoc analysis was done,
comparing all the sublines to the pcDNA3 subline.
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